Company intelligence / Profile preview

Proximagen

London, England, United Kingdomorpha.net ↗

Ownership: Private
Development stage: Phase 3

Overview

Proximagen was a UK-based biotech/pharma company focused on developing novel therapeutics—primarily small molecules—for central nervous system diseases and inflammatory conditions. Its pipeline included candidates targeting CXCR4, VAP‑1, M1 and serotonin receptors. The company initiated several clinical trials but ultimately discontinued all programs and was dissolved in October 2020.[3][4][5]

Therapeutic areas: RheumatologyOphthalmologyEndocrinologyOncologyNeurology
Modalities: small molecules
Industry: Biotech

Drug pipeline

2 assets

PRX00933

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

H. Lundbeck A/S (strategic partnership)Altacor Limited (collaborative R&D agreement for glaucoma program)BrainCells Inc. (“sabcomeline” sale/purchase agreement)

Beyond the preview

Go deeper on Proximagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proximagen.

Explore the full profile